New drug combo aims to boost immune system against hard-to-treat prostate cancer
NCT ID NCT05445609
First seen Sep 30, 2025 · Last updated May 17, 2026 · Updated 30 times
Summary
This study tests whether combining vidutolimod and nivolumab can help the immune system attack and destroy prostate cancer cells that have spread to other parts of the body. The trial includes men with metastatic castration-resistant prostate cancer who have already tried other treatments. The goal is to see if this drug pair can shrink tumors or slow the disease, but the study is currently on hold.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.